Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 2/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ERN1 | O75460 | 1/20 | 0.46 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.46 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL963885 | 0.91 | F10 (0.51) | F10SIGMAR1HRH3MAPK1KMT2A | |
| SCHEMBL960760 | 0.89 | GPR52 (0.53) | F10SIGMAR1HRH3KMT2APOLB | |
| SCHEMBL960213 | 0.89 | F10 (0.52) | F10SIGMAR1HRH3MAPK1KMT2A | |
| SCHEMBL960654 | 0.88 | F10 (0.55) | F10SIGMAR1HRH3KMT2AERN1 | |
| SCHEMBL959854 | 0.87 | F10 (0.51) | F10SIGMAR1HRH3MAPK1KMT2A | |
| SCHEMBL962179 | 0.85 | F10 (0.51) | F10SIGMAR1HRH3MAPK1KMT2A | |
| SCHEMBL12918993 | 0.82 | ABCB1 (0.52) | F10HRH3MAPK1POLBTP53 | |
| SCHEMBL12919090 | 0.82 | MAP4K4 (0.54) | KMT2ATLR9TLR7TLR8TP53 | |
| SCHEMBL12919003 | 0.80 | ABCB1 (0.53) | F10KMT2ATLR9TLR7TLR8 | |
| SCHEMBL958044 | 0.80 | PTGDR (0.51) | MAPK1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009421-A1 | COMPOUND HAVING 6-MEMBERED AROMATIC RING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20110009421-A1 | COMPOUND HAVING 6-MEMBERED AROMATIC RING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20110009421-A1 | COMPOUND HAVING 6-MEMBERED AROMATIC RING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-2253618-A1 | COMPOUND HAVING 6-MEMBERED AROMATIC RING | Takeda Pharmaceutical Company Limited (JP) | 2010-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009421-A1 | COMPOUND HAVING 6-MEMBERED AROMATIC RING | GPR4, NR3C2, NR5A2 | F10 2704/4885SIGMAR1 320/4885HRH3 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.